Guardant Health Inc GH Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Bell Michael Brian

Ownership Type:

Direct Ownership

Securities:

RESTRICTED STOCK UNITS

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-4,931

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Bell Michael Brian

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,703

Price:

$26.78
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Bell Michael Brian

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

4,931

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Potter Myrtle S

Ownership Type:

Direct Ownership

Securities:

RESTRICTED STOCK UNITS

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-68

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Potter Myrtle S

Ownership Type:

Direct Ownership

Securities:

RESTRICTED STOCK UNITS

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

68

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,600

Price:

$26.15
Mar 14, 2023 (filed on Mar 16, 2023)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

84,452

Price:

$26.33
Mar 14, 2023 (filed on Mar 15, 2023)

Insider Name:

Talasaz AmirAli

Ownership Type:

Indirect Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

4,250

Price:

$26.40
Mar 14, 2023 (filed on Mar 15, 2023)

Insider Name:

Talasaz AmirAli

Ownership Type:

Indirect Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

4,250

Price:

$26.40
Mar 14, 2023 (filed on Mar 15, 2023)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,500

Price:

$26.40

Filings by filing date

Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Bell Michael Brian

Ownership Type:

Direct Ownership

Securities:

RESTRICTED STOCK UNITS

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-4,931

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Bell Michael Brian

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-1,703

Price:

$26.78
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Bell Michael Brian

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

4,931

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Potter Myrtle S

Ownership Type:

Direct Ownership

Securities:

RESTRICTED STOCK UNITS

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-68

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Potter Myrtle S

Ownership Type:

Direct Ownership

Securities:

RESTRICTED STOCK UNITS

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

68

Price:

--
Mar 15, 2023 (filed on Mar 16, 2023)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,600

Price:

$26.15
Mar 14, 2023 (filed on Mar 16, 2023)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

84,452

Price:

$26.33
Mar 14, 2023 (filed on Mar 15, 2023)

Insider Name:

Talasaz AmirAli

Ownership Type:

Indirect Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

4,250

Price:

$26.40
Mar 14, 2023 (filed on Mar 15, 2023)

Insider Name:

Talasaz AmirAli

Ownership Type:

Indirect Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

4,250

Price:

$26.40
Mar 14, 2023 (filed on Mar 15, 2023)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

8,500

Price:

$26.40

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	3100 Hanover Street PALO ALTO CA 94304
Tel:	1-657-2545417
Website:	https://guardanthealth.com
IR:	See website

Key People

Helmy A. Eltoukhy Chairman of the Board, Co-Chief Executive Officer	Amirali Talasaz President, Co-Chief Executive Officer, Director	Michael Bell Chief Financial Officer
John Gomes Saia Senior Vice President, General Counsel, Corporate Secretary	Craig Eagle Chief Medical Officer	Christopher Freeman Chief Commercial Officer

Business Overview

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company's GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.

Financial Overview

For the fiscal year ended 31 December 2022, Guardant Health Inc revenues increased 20% to $449.5M. Net loss increased 61% to $654.6M. Revenues reflect United States segment increase of 19% to $420.6M, International segment increase of 37% to $28.9M. Higher net loss reflects Research and development expense increase of 42% to $347.2M (expense), Sales and marketing expense increase of 56% to $274.4M (expense).

Employees:	1,793 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$2,485M as of Dec 31, 2022
Annual revenue (TTM):	$449.54M as of Dec 31, 2022
EBITDA (TTM):	-$508.39M as of Dec 31, 2022
Net annual income (TTM):	-$654.59M as of Dec 31, 2022
Free cash flow (TTM):	-$386.92M as of Dec 31, 2022
Net Debt Last Fiscal Year:	$126.16M as of Dec 31, 2022
Shares outstanding:	102,663,734 as of Feb 17, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization